Asieris Pharmaceuticals is dedicated to becoming a China-based biotech company with significant global impacts on anti-cancer treatments. Our primary R&D strategy is to leverage the extensive knowledge of "old drugs" for creating breakthrough innovations.
More Information
Technology
R&D Strategy
Therapeutic Areas
Product Pipeline
APL-1202

 
 
We have established our unique Research and Development Strategy with below advantages:

老药新用en  
- Superior Human Safety

- Reduced Development Risk

- Shorter R&D Cycle

  


Bladder cancer and
other genitourinary tumors



Tumor immunotherapy



Multi drug resistant infection

 

  APL-1202
(NMIBC/Prostate Cancer)

APL-1301
(Urogenital Cancers)

APL-1401
(Cancer Immunotherapy)

APL-1501
(Multi-drug-Resistance Infection)
product pipeline  



         APL-1202 is the first oral drug in the world for the treatment of non-muscle-invasive bladder cancer (NMIBC), it is recognized as a breakthrough in bladder cancer therapy to relieve the pain of relapsed patients with superior efficacy.

    Patients Recruitment
for APL-1202 Pivotal Trial
 
(Results of a finished Phase II trial showed that) Comparing to current invasive intravesical chemotherapy , APL-1202 showed significant efficacy and superior human safety for NMIBC patients, Its oral administration is convenient and safe, without causing pain or injury to urethra.
 
Currently Our APL-1202 pivotal clinical trial has been initiated and now for patient recruitment. If you are interested and need more information, please click here.
  - Unmet Medical Needs
  - Great Clinical Advantages
  - Clinical Development Update
十二五 英文

Collaboration
We sincerely welcome the opportunity to partner with you.
News Release
-   Asieris Announced Follow-on Investment to its B Round Funding
-   Asieris Announced Appointment of Dr. Yijun Deng as VP of New Drug Discovery
-   Notice of Relocation of Our Shanghai Office
Media Report